《大行報告》麥格理上調信達生物(01801.HK)目標價至76.01元 重申為行業首選
麥格理發表研報,重申信達生物(01801.HK)為其行業首選,指出其產品線豐富,近期將有新產品面市,在研項目覆蓋早期創新技術及後期臨床試驗階段,而且公司已錄得收入,認為具有長期吸引力。
該行指,信達生物年初至今股價已累升128%,拋離同業約70%升幅,指出其創新腫瘤PD-1單抗藥物達伯舒(Tyvyt)已得到禮來製藥的前期付款和潛在里程碑付款,預期未來產品收入將繼續增長,潛力可觀,目標價由60.49元上調至76.01元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.